20405 ⎘
Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom; Quinolines; Isoquinolines Morphinan derivatives, e.g. morphine, codeine
Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
#902Bupropion as a modulator of drug activity
#903Bupropion as a modulator of drug activity
#904Sulfur (VI) fluoride compounds and methods for the preparation thereof
#905Abuse-proofed oral dosage form
#906Tamper resistant pharmaceutical formulations
#907Levorphanol prodrugs and processes for making and using them
#908COMPOSITIONS, DEVICES, AND METHODS FOR THE TREATMENT OF OVERDOSE AND REWARD-BASED DISORDERS
#909CANCER TREATMENT
#910Morphinan Derivatives with High Oral Bioavailability
#911LOCAL AND REGIONAL ANESTHESIA AND ANALGESIA
#912Buccal swab delivery system
#913ENHANCEMENT OF IMPAIRED MOTOR AND MENTAL FUNCTIONS, USING DEXTROMETHORPHAN AND OXIDASE ENZYME INHIBITOR
#914OPIOID FORMULATIONS
#915ABUSE-PROOFED DOSAGE FORM
#916Eplerenone for phenotyping of CYP3A5 enzyme activity in saliva samples
#917Process for preparing a drug delivery composition
#918Pyrazine-containing compound
#919Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
#920PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF DEPRESSION, ANXIETY, AND NEURODEGENERATIVE DISORDERS
#921Butyrylcholinesterase inhibitors for treatment of opioid use disorder
#922ABUSE-DETERRENT COMPOSITIONS
#923Dry powder compositions for intranasal delivery
#924Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides
#925Smart broadcast device
#926MULTIDIRECTIONAL MUCOSAL DELIVERY DEVICES AND METHODS OF USE
#927Bupropion as a modulator of drug activity
#928Methods of increasing satellite cell proliferation with vorinostat or bosutinib
#929Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids
#930SUSTAINED RELEASE BUPRENORPHINE MICROSPHERES (SRBM) AND METHODS OF USE THEREOF
#931LOW-TEMPERATURE STABLE OPIOID ANTAGONIST SOLUTIONS
#932PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF AGITATION IN DEMENTIA
#933PHARMACEUTICAL FORMULATION FOR A SOLID DOSAGE FORM OF OPIOID RECEPTOR ANTAGONISTS
#934Methods for administering weight loss medications
#935Methods and systems for providing personalised medicine to a patient
#936Sleep disorder treatment and prevention
#937Pharmaceutical composition for sustained release delivery of buprenorphine
#938ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS
#939ABUSE-DETERRENT DRUG FORMULATIONS
#940Device for deterring abuse of drugs
#941MORPHINE FORMULATIONS
#942Opioid formulations
#943Morphinan Derivatives for the Treatment of Drug Overdose
#944TREATMENT OF OPIOID USE DISORDER, OPIOID WITHDRAWAL SYMPTOMS, AND CHRONIC PAIN
#945Nanopore Delivery Device
#946TAMPER-RESISTANT DOSAGE FORM WITH IMMEDIATE RELEASE AND RESISTANCE AGAINST SOLVENT EXTRACTION
#947PROCESSES FOR PREPARING MORPHINAN-6-ONE PRODUCTS WITH LOW LEVELS OF a,ß-UNSATURATED KETONE COMPOUNDS
#948BUPROPION AS A MODULATOR OF DRUG ACTIVITY
#949Abuse deterrent morphine sulfate dosage forms
#950AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF OPIOID INDUCED DYSFUNCTIONS
#951METHOD FOR TREATING NEONATAL OPIOD WITHDRAWAL SYNDROME
#952Thiophene compounds for long-acting injectable compositions and related methods
#953Opioid ketal compounds and uses thereof
#954Dextromethorphan transdermal delivery device
#955Opioid ketal compounds and uses thereof
#956Opioid taper regimen
#957Methods and compositions for maintaining opioid efficacy in the treatment of pain
#958Pain Medicine Combination and Uses Thereof
#959TRANSDERMAL DELIVERY SYSTEM
#960Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
#961SUBLINGUAL AND BUCCAL FILM COMPOSITIONS
#962Devices and methods for delivery of pharmaceutical compositions
#963TRANSDERMAL DELIVERY SYSTEM COMPRISING BUPRENORPHINE
#964MICRONEEDLE ARRAY HAVING AN ACTIVE INGREDIENT IN THE FORM OF SALTS
#965Enteric combination therapy
#966Treatment of opioid addiction using fibroblasts and products thereof
#967Bupropion as a modulator of drug activity
#968System comprising a pre-fillable syringe and a package for the pre-fillable syringe
#969System comprising a pre-fillable syringe and a package for the pre-fillable syringe
#970Methods of treating acute or chronic pain
#971PHARMACEUTICAL COMPOSITIONS COMPRISING A DEXTROMETHORPHAN COMPOUND AND QUINIDINE FOR THE TREATMENT OF AGITATION IN DEMENTIA
#972Combination for treating pain
#973STABILIZED TRANSDERMAL DELIVERY SYSTEM
#974PHARMACEUTICAL COMPOSITIONS COMPRISING DELAYED RELEASE GELLING AGENT COMPOSITIONS
#975PATCH DEVICES, METHODS AND APPARATUS FOR FORMING, AND TESTING PHARMACEUTICAL AGENT DELIVERY PATCH DEVICES
#976TRANSORAL DOSAGE FORMS COMPRISING SUFENTANIL AND NALOXONE
#977TAMPER-RESISTANT DOSAGE FORM WITH IMMEDIATE RELEASE AND RESISTANCE AGAINST SOLVENT EXTRACTION
#978SYSTEMS AND METHODS FOR ATTENUATING OPIOID-INDUCED EUPHORIA
#979USE OF MORPHINANS FOR TREATING COCAINE ADDICTION, PRURITIS, AND SEIZURE DISORDERS
#980PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
#981Tableted chewing gum with enhanced delivery of cannabinoids
#982Method of producing tableted cannabinoid chewing gum
#983Tableted cannabinoid chewing gum with polyvinyl acetate elastomer plasticizers
#984Pharmaceutical compositions for treating pain
#985TAMPER-RESISTANT DOSAGE FORM WITH IMMEDIATE RELEASE AND RESISTANCE AGAINST SOLVENT EXTRACTION
#986Extended release, abuse deterrent dosage forms
#987Compositions and kits useful for treatment of respiratory illness
#988Arylfluorosulfate compounds and methods
#989Compositions and methods for nasal administration of drugs to brain and for systemic effect
#990Abuse-deterrent pharmaceutical compositions
#991Intranasal epinephrine formulations and methods for the treatment of disease
#992PHARMACEUTICAL CAPSULE CONTAINING AT LEAST TWO TABLETS
#993TRANSMUCOSAL DRUG DELIVERY DEVICES FOR USE IN CHRONIC PAIN RELIEF
#994TRANSDERMAL DELIVERY SYSTEM
#995Pharmaceutical resinate compositions and methods of making and using thereof
#996Naloxegol oxalate and solid dispersion thereof
#997HYDROGEL-FORMING COMPOSITION FOR CONTROLLED RELEASE
#998Bupropion as a modulator of drug activity
#999TRANSDERMAL DELIVERY SYSTEM INCLUDING AN EMULSIFIER
#1000BUPROPION AS A MODULATOR OF DRUG ACTIVITY
#1001BUPROPION AS A MODULATOR OF DRUG ACTIVITY
#1002Compositions for treating CMT and related disorders
#1003Extended release compositions of opioid antagonists and phosphodiesterase 5 inhibitors
#1004Buprenorphine transdermal delivery system
#1005Transdermal formulation for delivery of hydrophobic compounds and process for the preparation thereof
#1006Long-acting non-aqueous injectable formulations and use thereof
#1007PHARMACEUTICAL FORMULATIONS COMPRISING OPIOID RECEPTOR AGONIST AS ACTIVE INGREDIENTS, METHODS OF MANUFACTURE AND THERAPEUTIC USES THEREOF
#1008Combined herbal and pharmaceutical composition and method
#1009Bupropion as a modulator of drug activity
#1010Bupropion as a modulator of drug activity
#1011Bupropion as a modulator of drug activity
#1012PHARMACEUTICAL COMPOSITIONS
#1013Bupropion as a modulator of drug activity
#1014REDUCTION OF ALPHA, BETA-UNSATURATED KETONE LEVELS IN MORPHINAN DERIVATIVE COMPOSITIONS
#1015COATED PARTICLES
#1016Bupropion as a modulator of drug activity
#1017Bupropion as a modulator of drug activity
#1018Bupropion as a modulator of drug activity
#1019Bupropion as a modulator of drug activity
#1020Bupropion as a modulator of drug activity
#1021Bupropion as a modulator of drug activity
#1022Bupropion as a modulator of drug activity
#1023METHODS OF SAFELY TRANSITIONING A SUBJECT TO BUPRENORPHINE
#1024ABUSE-PROOFED DOSAGE FORM
#1025Method of treatment and dosage forms thereof
#1026Glycine receptor modulators and methods of use
#1027Non-readherable adhesive patch
#1028PHARMACEUTICAL COMPOSITIONS
#1029Device and method for the treatment of substance use disorders
#1030TREATMENTS FOR DEPRESSION AND OTHER DISEASES WITH A LOW DOSE AGENT
#1031Method for treating post-traumatic stress disorder
#1032COMPOSITIONS AND METHODS FOR MINIMIZING OR REVERSING AGONIST-INDUCED DESENSITIZATION
#1033METHODS AND COMPOSITIONS FOR POTENTIATING CNS DRUGS AND REDUCING THEIR SIDE EFFECTS
#1034ABUSE-PROOFED DOSAGE FORM
#1035Digital Therapeutic Component to Optimize Induction of Buprenorphine-Containing Products
#1036Targeting α2δ-1-bound glutamate receptors for treating diseases and disorders
#1037PHARMACEUTICAL FORMULATIONS FOR SUSTAINED RELEASE OF SEBACOYL DINALBUPHINE ESTER
#1038Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
#1039Cannabinoid derivatives and methods for their preparation
#1040FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF
#1041(+)-morphinans as antagonists of Toll-like receptor 9 and therapeutic uses thereof
#1042Percutaneous absorption composition
#1043FLT3 INHIBITORS FOR IMPROVING PAIN TREATMENTS BY OPIOIDS
#1044SUBLINGUAL CANNABINOID COMPOSITIONS
#1045PHARMACEUTICAL DOSAGE FORMS COMPRISING POLY(EPSILON-CAPROLACTONE) AND POLYETHYLENE OXIDE
#1046USE OF METHYLNALTREXONE TO ATTENUATE TUMOR PROGRESSION
#1047Acylated glucagon analogues
#1048MetAP2 inhibitors and methods of treating obesity
#1049Immediate release abuse-deterrent granulated dosage forms
#1050ABUSE RESISTANT TRANSMUCOSAL DRUG DELIVERY DEVICE
#1051Systems and Methods for Treating an Opioid-Induced Adverse Pharmacodynamic Response
#1052THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS
#1053SACCHARIDE-BASED, ORAL MUCOADHESIVE DELIVERY SYSTEM FOR PHARMACEUTICAL COMPOSITIONS
#1054Combination of dextromethorphan and bupropion for treating depression
#1055Manufacturing process of formulation having improved content uniformity
#1056BUPROPION AND DEXTROMETHORPHAN FOR TREATING NICOTINE ADDICTION
#1057Compositions for drug administration
#1058Compositions and methods for opioid antagonist delivery
#1059Biguanide compositions and methods of treating metabolic disorders
#1060Anti-inflammatory pharmaceutical compositions and methods of administration
#1061Pharmaceutical formulation containing gelling agent
#1062PECTIN GUMMY COMPOSTION AND METHODS OF MAKING AND USING THEREOF
#1063GELATIN GUMMY COMPOSTION AND METHODS OF MAKING AND USING THEREOF
#1064ABUSE-RESISTANT MUCOADHESIVE DEVICES FOR DELIVERY OF BUPRENORPHINE
#1065PHARMACEUTICAL COMPOSITIONS
#1066Emergency devices
#1067Modified release formulations containing drug-ion exchange resin complexes
#1068ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE
#1069Pramipexole for Use in the Treatment of Pain
#1070Patch
#1071Encased tamper resistant controlled release dosage forms
#1072LIQUISOFT CAPSULES
#1073Diversion-resistant opioid formulations
#1074Compositions of a polyorthoester and an aprotic solvent
#1075Abuse and misuse deterrent transdermal systems
#1076Extended relief dosage form
#1077Injectable long-acting naltrexone microparticle compositions
#1078Assay to identify anti-cancer agents
#1079DIAGNOSTIC METHODS, THERAPEUTIC AGENTS AND USES THEREOF
#1080Polysubunit opioid prodrugs resistant to overdose and abuse
#1081Pharmaceutical compositions and methods
#1082TRANSPORE DELIVERY OF DRUGS AND USES THEREOF
#1083AGENT THAT INCREASES THE EXPRESSION OF THE BCL2-ASSOCIATED AGONIST OF CELL DEATH FOR THE TREATMENT OF CANCER
#1084Agent that increases the expression of the opioid kappa 1 for the treatment of cancer
#1085Combination for use in the treatment of lung cancer
#1086PARTICLES CONTAINING AN OPIOID RECEPTOR ANTAGONIST AND METHODS OF USE
#1087ORAL PHARMACEUTICAL DOSAGE FORMS
#1088OXIDATION-STABILIZED TAMPER-RESISTANT DOSAGE FORM
#1089Methods of treating overweight and obesity
#1090Smart broadcast device
#1091Multifunctional aminoquinoline therapeutic agents
#1092ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS
#1093ABUSE-DETERRENT DRUG FORMULATIONS
#1094Liquid naloxone spray
#1095Opioid compositions resistant to overdose and abuse
#1096USE OF AMISULPRIDE AS AN ANTI-EMETIC
#1097Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
#1098Abuse deterrent immediate release capsule dosage forms
#1099Injectable flowable composition comprising buprenorphine
#1100Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
#1101Noncrushable pill formulations
#1102Oral formulations of kappa opioid receptor agonists
#1103Morphinan derivative
#1104Carboxylic diarythiazepineamines as mixed mu- and delta-opioid receptor agonists
#1105Methods and kits for treating pain
#1106IMMEDIATE RELEASE ABUSE DETERRENT TABLET
#1107OLIGOMER-OPIOID AGONIST CONJUGATES
#1108Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders
#1109CANNABINOID RECEPTOR MODULATORS
#1110METHODS OF SAFELY TRANSITIONING A SUBJECT TO BUPRENORPHINE
#1111PHARMACEUTICAL PREPARATIONS OF SEBACOYL DINALBUPHINE AND ACETAMINOPHEN AND METHODS FOR TREATING PAIN
#1112Process for preparing oxycodone compositions
#1113MULTIDIRECTIONAL MUCOSAL DELIVERY DEVICES AND METHODS OF USE
#1114Preparation method of naltrexone implants
#1115Compositions and methods for the treatment of opioid overdose
#1116Method for Treating a GD2 Positive Cancer
#1117Treating pain in patients with hepatic impairment
#1118Methylnaltrexone nasal formulations, methods of making, and use thereof
#1119Pharmaceutical Compositions
#1120Patch
#1121PHARMACEUTICAL COMPOSITIONS
#1122Opioid ketal compounds and uses thereof
#1123System for the transdermal delivery of active ingredient
#1124Compositions and methods for the treatment of Zellweger spectrum disorder
#1125CHEMICALLY STABLE COMPOSITIONS OF A PHARMACEUTICAL ACTIVE AGENT IN A MULTI-CHAMBERED DELIVERY SYSTEM FOR MUCOSAL DELIVERY
#1126APOMORPHINE PLUS BUSPIRONE COMBINATION FOR MEMORY REVIVAL
#1127Combination treatments for opioid crisis
#1128ABUSE-PROOFED ORAL DOSAGE FORM
#1129TAMPER-RESISTANT DOSAGE FORM FOR OXIDATION-SENSITIVE OPIOIDS
#1130Extended release, abuse deterrent pharmaceutical compositions
#1131PHARMACEUTICAL FORMULATIONS FOR SUSTAINED RELEASE OF SEBACOYL DINALBUPHINE ESTER
#1132TAMPER-RESISTANT DOSAGE FORM WITH IMMEDIATE RELEASE AND RESISTANCE AGAINST SOLVENT EXTRACTION
#1133Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods of making and use thereof
#1134SUBLINGUAL APOMORPHINE
#1135Early treatment of CMT disease
#1136Sublingual and buccal film compositions
#1137THERAPEUTIC SIGMA 1 RECEPTOR AGONISTS FOR TREATING LONG QT SYNDROME TYPE 1, TYPE 2, TYPE 6, TYPE 8 AND RELATED CHANNELOPATHIES
#1138NASAL DRUG PRODUCTS AND METHODS OF THEIR USE
#1139TRANSMUCOSAL DRUG DELIVERY DEVICES FOR USE IN CHRONIC PAIN RELIEF
#1140METHODS FOR TREATING OPIOID ADDICTION
#1141Morphinan compounds
#1142TREATMENT OF CHRONIC COUGH, BREATHLESSNESS AND DYSPNEA
#1143Formulations Containing Expectorants or Decongestants
#1144BUPROPION AS A MODULATOR OF DRUG ACTIVITY
#1145Naphthylenyl compounds for long-acting injectable compositions and related methods
#1146TREATMENT OF THE PRURITIC SYMPTOMS OF LIVER DISEASE
#1147Abuse resistant capsule
#1148TAMPER-RESISTANT DOSAGE FORM WITH IMMEDIATE RELEASE AND RESISTANCE AGAINST SOLVENT EXTRACTION
#1149Three-dimensional microfluidics devices for the delivery of actives
#1150Three-dimensional microfluidics devices for the delivery of actives
#1151METHOD AND USE OF BUPRENORPHINE IN TREATMENT OF CHRONIC PAIN
#1152PHARAMACEUTICAL COMPOSITIONS FOR TREATING CHRONIC PAIN AND PAIN ASSOCIATED WITH NEUROPATHY
#1153Base Composition for Tape Agent
#1154Butorphanol-containing patch
#1155Composition for patch preparation comprising drug, organic solvent, lipophilic mass base, and powder
#1156TWO-COMPONENT PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PAIN
#1157OPIOID AND ANTIEMETIC COMBINATION COMPOSITIONS FOR INCREASED PAIN RELIEF
#1158IMPROVED COMPOSITIONS AND METHODS FOR REDUCING OVERDOSE
#1159Acrylic Polymer Formulations
#1160PROCESSES FOR PREPARING MORPHINAN-6-ONE PRODUCTS WITH LOW LEVELS OF a,ß-UNSATURATED KETONE COMPOUNDS
#1161Opioid overdose monitoring
#1162Compositions and methods for weight loss in at risk patient populations
#1163Intranasal pharmaceutical dosage forms comprising naloxone
#1164Opioid overdose monitoring
#1165Opioid overdose monitoring
#1166PROCESS FOR IMPROVED OPIOID SYNTHESIS
#1167Combination therapy for treating cancer
#1168TRANSMUCOSAL DELIVERY DEVICES WITH ENHANCED UPTAKE
#1169Controlling water release from a dimensionally stable aqueous composition
#1170Sublingual films
#1171RAPIDLY DISINTEGRATING FORMULATIONS AND METHODS OF USE
#1172Methods of treating disease using auricular peripheral nerve field stimulation
#1173Emergency devices
#1174STABLE PHARMACEUTICAL FORMULATIONS OF METHYLNALTREXONE
#1175Increasing Drug Bioavailability In Naltrexone Therapy
#1176Opioid agonist / antagonist combination dosage forms
#1177Particulate materials
#1178Tamper resistant oral opioid agonist formulations
#1179High concentration suspension formulation for cold and flu soft gel capsule medications
#1180IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF BUPRENORPHINE
#1181TRANSDERMAL DOSAGE FORM
#1182TREATMENTS FOR DEPRESSION AND OTHER DISEASES WITH A LOW DOSE AGENT
#1183Mobile medical drug management systems and methods
#1184PEPTIDIC PROTEIN KINASE C INHIBITORS AND USES THEREOF
#1185DEUTERATED MORPHINAN COMPOUNDS FOR TREATING AGITATION
#1186COMPOSITIONS AND METHODS FOR MINIMIZING OR REVERSING AGONIST-INDUCED DESENSITIZATION
#1187Use of morphinan derivative for therapeutic treatment of opioid delta receptor agonist-related disease
#1188TRANSDERMAL PATCH
#1189Transdermal Therapeutic System with a Low Tendency to Spontaneously Crystallize
#1190UNIFORM FILMS FOR RAPID-DISSOLVE DOSAGE FORM INCORPORATING ANTI-TACKING COMPOSITIONS
#1191ABUSE-PROOFED DOSAGE FORM
#1192Method for inducing a sustained immune response
#1193Combination dosage form of a mu opioid receptor antagonist and an opioid agent
#1194Medical implant
#1195METHODS OF USING CANNABINOID CB2 RECEPTOR AGONIST COMPOSITIONS TO SUPPRESS AND PREVENT OPIOID TOLERANCE AND WITHDRAWAL IN A SUBJECT
#1196Oral formulations and lipophilic salts of methylnaltrexone
#1197Acetate salt of buprenorphine and methods for preparing buprenorphine
#1198Compositions and methods for reducing major adverse cardiovascular events
#1199Pharmaceutical Compositions for the Deterrence and/or Prevention of Abuse
#12008-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists